Skip to main content
All Guides

Clinical Science · Clinical Deep Dive

Beyond Monoamines: NMDA Antagonism, AMPA Throughput, and BDNF-Mediated Synaptogenesis in Esketamine Therapy

How SPRAVATO® (esketamine) CIII nasal spray engages glutamatergic neuroplasticity via NMDA receptor blockade, AMPA activation, and mTORC1-dependent spine formation.

Modal Mental HealthPublished · Updated 7 min read

Why monoamine reuptake inhibition hits a ceiling

For more than half a century, outpatient psychopharmacology centered on modulating serotonin, norepinephrine, and dopamine availability at the synaptic cleft. While SSRIs and SNRIs remain foundational first-line therapies, their clinical onset typically lags by 4 to 8 weeks—indicating that downstream transcriptional and neuroplastic adaptations, rather than acute neurotransmitter elevation, drive symptom resolution.

In chronic stress and Treatment-Resistant Depression (TRD), prefrontal and hippocampal pyramidal neurons exhibit dendritic atrophy and reduced synaptic spine density. When multiple monoaminergic agents fail to reverse this structural bottleneck, targeting the brain's primary excitatory neurotransmitter—glutamate—offers a mechanistically distinct entry point.

The disinhibition hypothesis: NMDA blockade to AMPA surge

Esketamine, the S-enantiomer of ketamine, acts as a non-competitive, use-dependent N-methyl-D-aspartate (NMDA) glutamate receptor antagonist. At therapeutic intranasal doses, esketamine preferentially blocks tonic NMDA receptors located on fast-spiking GABAergic interneurons.

Inhibiting these inhibitory interneurons produces a transient, controlled disinhibition of glutamatergic pyramidal neurons, resulting in a burst of extracellular glutamate. Because NMDA receptors remain transiently blocked, that glutamate surge preferentially activates postsynaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.

BDNF, TrkB, and mTORC1-driven synaptic remodeling

Increased AMPA throughput triggers voltage-dependent calcium influx, stimulating the activity-dependent release of Brain-Derived Neurotrophic Factor (BDNF). BDNF binds to TrkB receptors and activates the mammalian target of rapamycin complex 1 (mTORC1) signaling cascade, upregulating synaptic protein synthesis and promoting rapid synaptogenesis in prefrontal circuits.

This neurobiological sequence helps explain why SPRAVATO® (esketamine) CIII nasal spray can produce clinically meaningful symptom reductions far more rapidly than traditional oral antidepressants, and why it is FDA-approved for both adult TRD and Major Depressive Disorder with acute suicidal ideation or behavior (MDSI).

  • Transient glutamate surge and AMPA activation initiate rapid neuroplasticity
  • Administered alongside an oral antidepressant under the FDA SPRAVATO® REMS Program
  • Mandatory 2-hour post-dose observation in a private REMS suite monitors blood pressure, sedation, and dissociation
  • Patients must arrange a ride home and avoid driving until the next day after a restful sleep

Common Questions

SSRIs and SNRIs inhibit monoamine reuptake, whereas SPRAVATO® (esketamine) is an NMDA receptor antagonist that stimulates AMPA-mediated glutamate signaling and BDNF-linked synaptogenesis.

More Patient Guides

All guides